Glycine Side Effects

Reported Glycine side effects

Glycine has an exceptional safety profile across extensive clinical use. Doses up to 60 g daily have been used in schizophrenia trials without systematic serious adverse effects. For typical supplementation doses (3-15 g daily), side effects are uncommon and generally mild. Common mild side effects (typically at higher doses): Gastrointestinal discomfort: Mild nausea or loose stools occur in a small percentage of users, particularly with doses above 15 g taken without food. Usually resolves with dose reduction, splitting doses, or taking with food. Soft stools or mild diarrhea: May occur at higher doses, particularly when starting at full dose rather than titrating up. Mild sedation: Dose-dependent; typical at bedtime doses of 3-10 g. Desirable for sleep applications but may be undesirable for daytime use in some individuals. Dream intensity changes: Some users report more vivid or memorable dreams at bedtime doses. Generally neutral to positive but can be disconcerting for some. Sweet taste: Glycine has a naturally sweet taste (about 70% the sweetness of sucrose). This is the "side effect" of the compound's organoleptic properties rather than a true adverse effect. Uncommon side effects: Morning grogginess: Possible at higher bedtime doses (>10 g) in sensitive individuals. Lightheadedness: Rare; may relate to peripheral vasodilation (the same mechanism responsible for glycine's pre-sleep temperature reduction). Headache: Occasional reports; unclear mechanism. Mild ammonia elevation: Glycine is metabolized partially by the glycine cleavage system producing ammonia. In patients with advanced liver disease or urea cycle disorders, this could theoretically be problematic. Generally not clinically relevant in healthy individuals. Rare but notable concerns: Schizophrenia adjunctive use — very high doses: Doses of 30-60 g daily used in schizophrenia trials have been associated with occasional GI symptoms, mild edema, and sedation. Most trials have completed without serious adverse effects. These extreme doses are not applicable to general consumer supplementation. GlyNAC protocol specific considerations: Combining glycine ~10 g with NAC ~1200 mg daily (per Sekhar protocols) has been well tolerated in older adults. Minor GI symptoms are the most common issue. Some patients experience initial fatigue that typically resolves within 1-2 weeks. Perioperative use: Glycine has been used safely in perioperative protocols. No specific anesthetic interactions documented, but discussion with surgical team is appropriate as with all supplements. Theoretical concerns: NMDA receptor activation: While glycine is a co-agonist at NMDA receptors (requiring glutamate for activation), excessive activation could theoretically contribute to excitotoxicity in settings of brain ischemia or trauma. Clinical evidence of harm is absent. This concern is largely theoretical in physiological states. Cancer cell proliferation: Glycine is required for rapid cell division including tumor cell growth. Some evidence suggests glycine supplementation could hypothetically support cancer cell proliferation in established cancer. Clinical implications are unclear; cancer patients should discuss with oncology team. Bipolar disorder: Limited evidence regarding effects on mood cycling in bipolar disorder. Theoretical concern about NMDA receptor modulation and mood; not a documented clinical issue. Homocysteine metabolism: Glycine participates in one-carbon metabolism. Very high doses in patients with MTHFR polymorphisms or B-vitamin deficiencies could theoretically affect homocysteine levels, though this has not been a documented clinical issue. Trimethylglycine (TMG, betaine) interaction: Not a concern; these are different compounds despite the naming similarity. TMG is N,N,N-trimethylglycine, distinct from plain glycine. Liver conditions: Patients with advanced hepatic encephalopathy or urea cycle disorders may have impaired ammonia handling. Discuss with hepatology before high-dose glycine. Drug interactions: Clozapine and other strong antipsychotics: Combined use with high-dose glycine has been done in schizophrenia trials without systematic problems. Caution with clozapine because of its own pharmacological complexity. Strychnine: Glycine receptor antagonism is the mechanism of strychnine toxicity. Glycine would not reverse strychnine poisoning but obviously this is not a practical concern. Benzodiazepines and CNS depressants: Mild additive sedation possible at higher glycine doses. Usually well tolerated. Alcohol: No specific interaction, but both affect CNS function. Avoid combining very high-dose glycine with substantial alcohol. Sodium valproate and other anticonvulsants: No documented interactions, but glycine's NMDA effects could theoretically interact with anticonvulsant mechanisms. Discuss with neurology if on seizure medications. Isotretinoin and other hepatotoxic drugs: No specific interaction; glycine supports hepatic detoxification. Methadone and opioid replacement therapy: No documented interaction. Bile acid sequestrants: Theoretical reduction in absorption; separate by 2 hours. Levodopa and Parkinson medications: No documented interactions. Populations requiring caution: Pregnancy and lactation: Glycine is naturally present in breast milk and is important for fetal development. Supplementation within typical ranges (3-10 g daily) is considered safe during pregnancy and lactation. Higher doses (>15 g) should only be used with obstetric input. Pediatrics: Infant formula contains glycine naturally. Pediatric supplementation beyond that is not routine; should be guided by pediatric specialists. Advanced liver disease: Particularly in hepatic encephalopathy, glycine metabolism may be altered. Discuss with hepatology before supplementation. Advanced kidney disease: Generally well tolerated; dose adjustment may be appropriate in very advanced disease or dialysis. Urea cycle disorders: Contraindicated or requires specialist management due to ammonia handling concerns. Schizoaffective or psychotic disorders: Paradoxically, glycine may benefit negative symptoms (as tested in schizophrenia), but could theoretically affect acute psychosis. Use under psychiatric supervision. Signs to monitor: GI symptoms at initiation—if persistent despite dose reduction and food co-administration, consider discontinuation Excessive sedation (reduce bedtime dose or move to different timing) Any neurological changes (uncommon but worth noting) Blood sugar changes if diabetic (mild glucose reduction expected; significant changes may require medication adjustment) When to reduce or discontinue: Persistent GI discomfort despite food co-administration and dose reduction Excessive morning grogginess Unwanted changes in dream quality or vividness Pregnancy with doses above 15 g daily unless specifically prescribed Development of new medical conditions that affect amino acid handling Withdrawal considerations: No physiological withdrawal syndrome has been documented with glycine discontinuation. Benefits (sleep, glutathione status, collagen synthesis support) may gradually decline over weeks after stopping, but there is no acute withdrawal. No need to taper. Quality and contamination concerns: Pharmaceutical-grade and food-grade glycine are well-regulated Purity is typically high (>99%) for reputable manufacturers Rare reports of contamination with other amino acids or fillers in discount products Third-party testing (USP, NSF) provides additional quality assurance

When to continue, reduce, or stop Glycine

Glycine contraindications

Glycine has one of the cleanest safety profiles among widely used supplements. Absolute contraindications are rare, and most situations requiring caution are relative rather than absolute. Absolute contraindications: Known hypersensitivity to glycine or excipients in a specific product (extremely rare) Urea cycle disorders (unless specifically prescribed by specialist)—glycine metabolism can contribute to ammonia load Active severe hepatic encephalopathy with elevated ammonia Strong relative contraindications (medical supervision recommended): Advanced liver disease (Child-Pugh C): Glycine's contribution to ammonia production through the glycine cleavage system could theoretically worsen encephalopathy. Moderate doses may be acceptable under hepatology supervision. Advanced chronic kidney disease / dialysis: Altered amino acid handling; dose adjustment likely needed. Consult nephrology. Acute schizophrenia or acute psychotic states: Chronic high-dose glycine may benefit negative symptoms, but acute decompensated psychosis requires emergency psychiatric management, not supplement introduction. Pregnancy with very high-dose protocols: Standard doses (3-10 g) considered safe and even beneficial during pregnancy. High-dose protocols (>15 g) should be held or held pending obstetric input. Trimethylglycine (TMG) / betaine naming confusion: These are different compounds despite the naming. TMG is specifically contraindicated or requires caution in some settings (e.g., very high homocysteine levels without appropriate workup) that don't apply to plain glycine. Situations requiring careful dose consideration: Older adults with polypharmacy: Multiple drug interactions (minor but worth considering). Start at lower doses, monitor for sedation. Patients with sleep apnea (untreated): Glycine's mild sedative effects at higher bedtime doses could theoretically worsen sleep apnea symptoms. Treat underlying sleep apnea (CPAP) before considering glycine for sleep. Patients on strong CNS depressants (benzodiazepines, opioids, barbiturates): Mild additive sedation possible at higher doses. Consider morning dosing instead of bedtime, or reduce dose. Type 1 diabetes: Limited data specifically in T1D. Some potential for glycine's insulin-sensitizing effects. Monitor glucose if starting; discuss with endocrinology. Established cardiovascular disease: Generally well-tolerated; may offer modest benefits. No specific contraindications beyond standard supplement review. Cancer (active treatment): Complex considerations. Glycine supports glutathione (could reduce chemotherapy efficacy for some agents that rely on oxidative damage) or could support healthy cell function. Discuss with oncology team. Autoimmune conditions: Generally safe. Some theoretical interest for lupus, rheumatoid arthritis via anti-inflammatory mechanisms; evidence is limited. Drug interactions requiring attention: Antipsychotic medications: Glycine has been safely combined with most antipsychotics in schizophrenia trials. Clozapine combinations have been less robustly beneficial but not harmful. Discuss with psychiatry. Benzodiazepines and barbiturates: Mild additive CNS depression at higher glycine doses. Usually well-tolerated. Opioid medications: Possible additive sedation. Usually not clinically significant at standard glycine doses. Alcohol: No specific interaction but both affect CNS and liver. Moderate use of both is acceptable; avoid combining very high doses. Bile acid sequestrants (cholestyramine, colesevelam): May theoretically reduce glycine absorption. Separate by 2 hours. Insulin and oral antidiabetics: Potential for additive glucose reduction. Monitor glucose when starting glycine in tightly-controlled diabetics. Levodopa and Parkinson's medications: Large neutral amino acids compete for blood-brain barrier transport. Theoretically, very high glycine doses could affect levodopa absorption, but clinical significance is typically minimal. Tricyclic antidepressants: No documented specific interactions. SSRIs and SNRIs: No documented specific interactions. NMDA modulators (memantine, ketamine): Glycine is a co-agonist at NMDA receptors. Theoretical interactions; clinical significance unclear. Discuss with prescriber. Diuretics: No documented specific interactions. ACE inhibitors and ARBs: No documented specific interactions. Statins: No documented specific interactions. Situations where glycine supplementation is NOT recommended: As a substitute for medical treatment: Glycine is an adjunctive supplement, not a replacement for prescribed medications for serious conditions (diabetes, schizophrenia, kidney disease). Very young children without specific medical indication: Infant formula contains glycine; pediatric supplementation beyond that is not evidence-based without specialist input. Acute decompensated liver disease with elevated ammonia: Avoid until ammonia levels stable and specialist guidance available. Urea cycle disorders: Avoid unless specifically prescribed as part of disorder management. When to stop glycine supplementation: Immediate discontinuation warranted for: Unexpected severe GI symptoms not responsive to dose reduction Excessive sedation interfering with daily function Elevated ammonia or signs of hepatic decompensation in patients with liver disease Development of new serious medical conditions that may affect amino acid handling Pregnancy with doses above 15 g daily unless specifically prescribed Gradual reduction reasonable for: Resolution of original indication Desire to reduce supplement burden Shift to dietary adequacy (increased dietary collagen, bone broth, etc.) Cost considerations Monitoring recommendations by use case: Foundational daily (3-10 g): No specific monitoring beyond annual complete health assessment. GlyNAC protocol (10 g + NAC): Baseline and 3-6 month labs for response assessment: glutathione (if available), inflammatory markers (hsCRP), metabolic panel, physical function. High-dose therapeutic (>15 g chronically): Monitoring specific to indication. Liver function periodically if prolonged high-dose use. Schizophrenia adjunctive (30-60 g): Psychiatric monitoring. Occasional labs for metabolic function. Pre-surgical considerations: Not typically required to hold glycine before surgery given clean pharmacology profile. Discuss with surgical team; some surgeons prefer discontinuation of most non-essential supplements 1-2 weeks preoperatively. Post-surgical resumption after GI function restored. Dose adjustments: Renal impairment: CrCl >60: no adjustment CrCl 30-60: monitor; consider reduction if any symptoms CrCl <30: reduce dose; specialist consultation Dialysis: specialist input required Hepatic impairment: Compensated cirrhosis: no specific adjustment; potentially beneficial Decompensated cirrhosis/encephalopathy: avoid or very careful specialist-supervised use Mild-moderate hepatitis: no specific adjustment Elderly: Generally no specific adjustment May be particularly responsive to GlyNAC protocol benefits Monitor for sedation effects, particularly with bedtime dosing Pediatric: Infant formula contains glycine naturally Beyond formula, pediatric dosing should be specialist-directed Not recommended for routine pediatric use without clinical indication Counseling points for new users: Expect subtle effects over weeks; glycine is not a rapid-acting supplement for most indications Sleep effects may be noticeable within days for some users Connective tissue effects take months of consistent use GlyNAC protocol effects on biomarkers typically evident at 3-6 months Higher doses are not necessarily better; most users do well at 3-10 g daily Combine with NAC for glutathione-focused applications Combine with collagen for connective tissue focus Safety profile is excellent; adjust based on tolerance and response

Why vendor quality drives Glycine side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Glycine side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .